FDA panel votes unanimously to make birth control pill available over the counter
The U.S. Food and Drug Administration's advisory panel voted unanimously to make the birth control pill Opill available over the counter, saying that the benefits outweigh the risks, The New York Times reports. "I think Opill has the potential to have a huge positive public health impact," said advisory committee member Kathryn Curtis.
While Opill manufacturer Perrigo called the outcome "groundbreaking," this doesn't mean the pill will be available just yet, CNN writes. The FDA is not required to listen to the advisory committee and will decide whether to make the pill available sometime in the summer. Some agency members are concerned about whether people will use the product as directed, especially those with health conditions and adolescents. "The FDA has been put in a very difficult position of trying to determine whether it is likely that women will use this product safely and effectively at the nonprescription setting," explained Dr. Karen Murry, deputy director of the FDA's office of nonprescription drugs.
The push to approve Opill is stronger than ever as many states have adopted extra-restrictive abortion bans following the overturning of Roe v. Wade (1973). Maternal healthcare has also reportedly been on a decline because of these laws. "I think this represents a landmark in our history of women's health," commented advisor Dr. Marjorie Gass said of the FDA progress. "Unwanted pregnancies can really derail a woman's life, and especially an adolescent's life."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"We are motivated by the millions of people who need easy access to safe and effective contraception," remarked Perrigo president and CEO Murray S. Kessler in a statement. "Today's outcome reflects Perrigo's steadfast commitment to women and people, and their health."
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
'The House under GOP rule has become a hostile workplace'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
The Shohei Ohtani gambling scandal is about more than bad bets
In The Spotlight The firestorm surrounding one of baseball's biggest stars threatens to upend a generational legacy and professional sports at large
By Rafi Schwartz, The Week US Published
-
Feds raid Diddy homes in alleged sex trafficking case
Speed Read Homeland Security raided the properties of hip hop mogul Sean "Diddy" Combs
By Peter Weber, The Week US Published
-
The alarming rise of cancer in young people
Under the radar Cancer rates are rising, and the cause is not clear
By Devika Rao, The Week US Published
-
How happy is Finland really?
Today's Big Question Nordic nation tops global happiness survey for seventh year in a row with 'focus on contentment over joy'
By Harriet Marsden, The Week UK Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Narcan is becoming harder to find at drugstores across America
Under the Radar The drug, also known as naloxone, reverses the effects of an opioid overdose
By Justin Klawans, The Week US Published
-
The lows of an unregulated high: Teens are using marijuana alternative delta-8
In the Spotlight More than 1 in 10 high school seniors have reported using the substance, which contains concentrated THC
By Justin Klawans, The Week US Published
-
OTC birth control arrives amid the battle over reproductive rights
Talking Points Opill will cost $19.99 a month. Democrats are pushing to make it cheaper.
By Joel Mathis, The Week US Published
-
What Florida is — and isn't — doing to curb the biggest measles outbreak in the US
Talking Points DeSantis appointee defies expert consensus to stop the spread
By Joel Mathis, The Week US Published
-
How Tehran became the world's nose job capital
Under the radar Iranian doctors raise alarm over low costs, weak regulation and online influence of 'Western beauty standards'
By Harriet Marsden, The Week UK Published